AstraZeneca Says Brilinta Premium Pricing Merited Based On Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
During its quarterly earnings call, the pharma pointed out that international reimbursement decisions have supported premium pricing over Plavix.